{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:23:01Z","timestamp":1791894181892,"version":"4.3.4"},"reference-count":31,"publisher":"Royal College of Psychiatrists","issue":"3","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych open"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Hyperprolactinaemia is a common adverse effect of antipsychotic medication, primarily resulting from dopamine D2 receptor blockade. It is characterised by menstrual irregularities, gynaecomastia, galactorrhoea and, with prolonged exposure, an increased risk of osteoporosis and breast cancer. When switching towards a prolactin-sparing antipsychotic is not feasible, adjunctive use of aripiprazole \u2013 a dopamine D2 partial agonist \u2013 has emerged as a validated strategy to mitigate hyperprolactinaemia without compromising antipsychotic efficacy. However, alternative options are needed for patients who cannot tolerate aripiprazole. Here we report the use of brexpiprazole, a dopamine D2 partial agonist structurally related to aripiprazole, to counteract paliperidone-induced hyperprolactinaemia effectively in a patient who developed a cutaneous reaction to aripiprazole. During the follow-up period with adjunctive brexpiprazole in combination with paliperidone, neither a recurrence of psychotic symptoms nor a reappearance of the skin reaction previously experienced with aripiprazole was observed.<\/jats:p>","DOI":"10.1192\/bjo.2026.11052","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:33:50Z","timestamp":1779082430000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":2,"title":["Brexpiprazole mitigates hyperprolactinaemia induced by paliperidone in a patient with a history of skin reaction to aripiprazole: case report introducing a new therapeutic approach"],"prefix":"10.1192","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3456-317X","authenticated-orcid":false,"given":"Marie","family":"Humbert-Claude","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009x7v589","id-type":"ROR","asserted-by":"publisher"}],"name":"Pharmacy of the Eastern Vaud Hospitals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Barb\u00e9","sequence":"additional","affiliation":[{"name":"Fondation de Nant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Cristina","family":"Ionescu","sequence":"additional","affiliation":[{"name":"Fondation de Nant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnoush","family":"Khasian","sequence":"additional","affiliation":[{"name":"Fondation de Nant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Timothy","family":"Khachouf","sequence":"additional","affiliation":[{"name":"Fondation de Nant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Blanc","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009x7v589","id-type":"ROR","asserted-by":"publisher"}],"name":"Pharmacy of the Eastern Vaud Hospitals"},{"id":[{"id":"https:\/\/ror.org\/01swzsf04","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Geneva, University of Lausanne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Lemoullec-Tourtier","sequence":"additional","affiliation":[{"name":"Fondation de Nant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7392-2418","authenticated-orcid":false,"given":"Nicolas","family":"Widmer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009x7v589","id-type":"ROR","asserted-by":"publisher"}],"name":"Pharmacy of the Eastern Vaud Hospitals"},{"id":[{"id":"https:\/\/ror.org\/01swzsf04","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Geneva, University of Lausanne"},{"id":[{"id":"https:\/\/ror.org\/05a353079","id-type":"ROR","asserted-by":"publisher"}],"name":"Lausanne University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"S2056472426110527_ref21","doi-asserted-by":"publisher","DOI":"10.5021\/ad.21.114"},{"key":"S2056472426110527_ref31","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160432"},{"key":"S2056472426110527_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.08.012"},{"key":"S2056472426110527_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2025.111349"},{"key":"S2056472426110527_ref28","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.183082"},{"key":"S2056472426110527_ref24","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312451442"},{"key":"S2056472426110527_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00241-8"},{"key":"S2056472426110527_ref7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.8.1542-a"},{"key":"S2056472426110527_ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00003"},{"key":"S2056472426110527_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2008.02.004"},{"key":"S2056472426110527_ref30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002062"},{"key":"S2056472426110527_ref12","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145706007115"},{"key":"S2056472426110527_ref14","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"S2056472426110527_ref1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088436"},{"key":"S2056472426110527_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12637"},{"key":"S2056472426110527_ref20","unstructured":"20 Lundbeck, H . A\/S, Rxulti (brexpiprazole) [Summary of Product Characteristics]. 2023, European Medicines Agency (EMA)."},{"key":"S2056472426110527_ref27","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.213793"},{"key":"S2056472426110527_ref19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"S2056472426110527_ref26","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.033175"},{"key":"S2056472426110527_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114215"},{"key":"S2056472426110527_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00812-1"},{"key":"S2056472426110527_ref9","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182970431"},{"key":"S2056472426110527_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"S2056472426110527_ref15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.16121358"},{"key":"S2056472426110527_ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.781946"},{"key":"S2056472426110527_ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s004060170049"},{"key":"S2056472426110527_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.12.033"},{"key":"S2056472426110527_ref8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05154yel"},{"key":"S2056472426110527_ref11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06071075"},{"key":"S2056472426110527_ref17","first-page":"30","article-title":"Brexpiprazole as a new serotonin-dopamine receptor modulator: considering the clinical relevance for metabolic parameters and prolactin levels","volume":"16","author":"Nakamura","year":"2019","journal-title":"Innov Clin Neurosci"},{"key":"S2056472426110527_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000979"}],"container-title":["BJPsych Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056472426110527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:33:53Z","timestamp":1779082433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056472426110527\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["S2056472426110527"],"URL":"https:\/\/doi.org\/10.1192\/bjo.2026.11052","relation":{},"ISSN":["2056-4724"],"issn-type":[{"value":"2056-4724","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e137"}}